A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group

T.M. Horton; J.P. Perentesis; A.S. Gamis; T.A. Alonzo; R.B. Gerbing; J. Ballard; K. Adlard; D.S. Howard; F.O. Smith; G. Jenkins; A. Kelder; G.J. Schuurhuis; J.A. Moscow

doi:10.1002/pbc.25117

A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group

T.M. Horton, J.P. Perentesis, A.S. Gamis, T.A. Alonzo, R.B. Gerbing, J. Ballard, K. Adlard, D.S. Howard, F.O. Smith, G. Jenkins, A. Kelder, G.J. Schuurhuis, J.A. Moscow

Hematology laboratory

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1754-1760
Journal	Pediatric Blood and Cancer
Volume	61
Issue number	10
DOIs	https://doi.org/10.1002/pbc.25117
Publication status	Published - 2014

Access to Document

10.1002/pbc.25117

Cite this

Horton, T. M., Perentesis, J. P., Gamis, A. S., Alonzo, T. A., Gerbing, R. B., Ballard, J., Adlard, K., Howard, D. S., Smith, F. O., Jenkins, G., Kelder, A., Schuurhuis, G. J., & Moscow, J. A. (2014). A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Pediatric Blood and Cancer, 61(10), 1754-1760. https://doi.org/10.1002/pbc.25117

@article{ad476b51b6964a34aff491a9a67f3a66,

title = "A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group",

author = "T.M. Horton and J.P. Perentesis and A.S. Gamis and T.A. Alonzo and R.B. Gerbing and J. Ballard and K. Adlard and D.S. Howard and F.O. Smith and G. Jenkins and A. Kelder and G.J. Schuurhuis and J.A. Moscow",

year = "2014",

doi = "10.1002/pbc.25117",

language = "Undefined/Unknown",

volume = "61",

pages = "1754--1760",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Horton, TM, Perentesis, JP, Gamis, AS, Alonzo, TA, Gerbing, RB, Ballard, J, Adlard, K, Howard, DS, Smith, FO, Jenkins, G, Kelder, A, Schuurhuis, GJ & Moscow, JA 2014, 'A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group', Pediatric Blood and Cancer, vol. 61, no. 10, pp. 1754-1760. https://doi.org/10.1002/pbc.25117

A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group. / Horton, T.M.; Perentesis, J.P.; Gamis, A.S. et al.

In: Pediatric Blood and Cancer, Vol. 61, No. 10, 2014, p. 1754-1760.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group

AU - Horton, T.M.

AU - Perentesis, J.P.

AU - Gamis, A.S.

AU - Alonzo, T.A.

AU - Gerbing, R.B.

AU - Ballard, J.

AU - Adlard, K.

AU - Howard, D.S.

AU - Smith, F.O.

AU - Jenkins, G.

AU - Kelder, A.

AU - Schuurhuis, G.J.

AU - Moscow, J.A.

PY - 2014

Y1 - 2014

U2 - 10.1002/pbc.25117

DO - 10.1002/pbc.25117

M3 - Article

C2 - 24976003

SN - 1545-5009

VL - 61

SP - 1754

EP - 1760

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 10

ER -